Fluconazole susceptibility of Candida spp. isolates collected over nine years in a teaching hospital of Ancona, Italy

Journal of Chemotherapy

Volumn 19, Issue 1, 2007, Pages 58-61

  Barchiesi, Francesco ^a   Arzeni, D ^a   Greganti, G ^a   Marigliano, A ^a   Tomassetti, S ^a   Spreghini, E ^a   Scalise, G ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Antifungal resistance; Antifungal susceptibility testing; Fluconazole

Indexed keywords

FLUCONAZOLE;

ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESISTANCE; DRUG SENSITIVITY; FUNGUS ISOLATION; HOSPITALIZATION; IN VITRO STUDY; ITALY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; UNIVERSITY HOSPITAL; YEAST;

EID: 33846999665     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.1.58     Document Type: Article

References (10)

1. Pfaller MA, Diekema DJ et al. Rare and emerging opportunistic fungal pathogens: concern for resistant beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42: 4419-4431.
2. Spelberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006; 42: 244-251.
3. Tortorano AM, Peman J, Bernhardt H et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23(4):317-22.
4. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J Clin Microbiol 2003; 41: 2176-2179.
5. Redding SW, Kirkpatrick WR, Seville S et al. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J Clin Microbiol 2003; 41: 619-622.
6. Hajjeh RA, Sofair AN, Harrison LH et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004; 42: 1519-1527.
7. Pfaller MA, Diekema DJ, Rinaldi MG et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005; 43(12): 5848-5859.
8. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2, 2nd ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
9. Tortorano AM, Prigitano A, Biraghi E, Viviani MA. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production. J Antimicrob Chemother. 2005; 56(4):777-9.
10. Tortorano AM, Rigoni AL, Biraghi E, Prigitano A, Viviani MA and the FIMUA-ECMM candidaemia study group. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 of non-albicans Candida isolates from blood. J Antimicrob Chemother. 2003; 52(4):679-682.